Investing
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Published:
Last Updated:
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and currently trading at $795.67.
The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock.
However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond.
That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030.
Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future.
Recent Eli Lilly Stock Updates and News
12/24/2024
Beginning in March 2025, some patients in Britain will have access to Mounjaro, Eli Lilly’s obesity drug, through the National Health Service (NHS). This follows approval from the UK’s health technology assessment body, which evaluates the cost-effectiveness of new treatments.
12/20/2024
The FDA has approved Eli Lilly’s obesity drug, Zepbound (tirzepatide), as the first treatment for obstructive sleep apnea in the U.S.
12/19/2024
The Food and Drug Administration (FDA) has reaffirmed its earlier decision that the shortage of tirzepatide (the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound) has ended. This decision means that most compounding pharmacies will be required to cease production of compounded tirzepatide within the next 90 days.
12/18/2024
Kinsula (donanemab-azbt), Eli Lilly’s Alzheimer’s medication, has been approved by China’s National Medical Products Administration. In addition, EVA Pharma, in collaboration with Eli Lilly, has received approval from the Egyptian Drug Authority for its insulin glargine injection. This approval marks a milestone in providing affordable insulin to millions of people with diabetes in low- and middle-income countries.
12/16/2024
Eli Lilly’s Omvoh (mirikizumab) has been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use to treat adults with moderate to severe Crohn’s disease. The drug was previously approved for ulcerative colitis in the U.S., Japan, and the EU.
12/13/2024
Recent reports show that Eli Lilly’s weight-loss drug Mounjaro is more popular in the UK than Wegovy by Novo Nordisk. Surveys suggest that users perceive Mounjaro to be more effective in weight loss, and online pharmacies have seen a shift to Mounjaro prescriptions.
12/12/2024
Ro, a telehealth company, has teamed up with Eli Lilly to improve patient access to Zepbound (tirzepatide). Through LillyDirect, patients can now obtain Zepbound at a self-pay price, making it more affordable.
12/11/2024
Eli Lilly’s experimental breast cancer drug, imlunestrant, has shown promising results in a Phase 3 clinical trial. When combined with Verezenio, the drug significantly extended the lives of patients with HER2-negative, ER-positive breast cancer compared to standard hormone-suppressing therapies.
12/10/2024
Eli Lilly plans to investigate the potential use of its popular weight-loss medications to treat addictive behaviors like smoking, alcohol abuse, and drug addiction. CEO Dave Ricks stated that these medications may have broader applications beyond weight loss and that the company will initiate clinical trials to explore these possibilities.
12/9/2024
Eli Lilly is planning to introduce Tirzepatide (or Mounjaro), the company’s diabetes and obesity drug, to the Indian market next year. The company has already received marketing authorization from Indian regulatory authorities for both Type 2 diabetes and obesity indications.
Eli Lilly’s Recent Stock Success
How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers:
| Share Price | Revenues* | Net Income* | |
| 2016 | $80.36 | $21.22 | $2.74 |
| 2017 | $77.55 | $19.94 | ($0.21) |
| 2018 | $122.13 | $21.49 | $3.23 |
| 2019 | $140.83 | $22.32 | $8.32 |
| 2020 | $206.46 | $24.54 | $6.19 |
| 2021 | $238.31 | $28.32 | $5.58 |
| 2022 | 329.07 | $28.54 | $6.25 |
| 2023 | $745.91 | $34.12 | $5.24 |
*Revenue and Net Income in Billions
Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price.
For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple.
This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation?
3 Key Drivers of Eli Lilly Stock
- Innovated Drug Pipeline: The current drug pipeline is loaded with several very high-potential drugs in development. Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential.
- Strategic Acquisitions: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth.
- Operational Efficiency: With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth.
Eli Lilly (LLY) Stock Price Prediction in 2025
The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 29.45% higher than today’s price of $795.67. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.67 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.
24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows:
| Endocrinology | $735/ share |
| Oncology | $122/ Share |
| Cardiovascular | $4/ Share |
| Neuroscience | $16/ Share |
| Immunology | $38/ Share |
| Others and Pipeline | $110/ Share |
| Cash | $17/ Share |
Eli Lilly’s Share Price Estimates 2025-2030
Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple.
| Revenue | Net Income | EPS | |
| 2025 | $52.8 | $17.29 | 19.11 |
| 2026 | $62.5 | $22.49 | 25.03 |
| 2027 | $70.87 | $27.12 | 30.39 |
| 2028 | $80.68 | $32.2 | 25.97 |
| 2029 | $87.99 | $36.45 | 40.58 |
| 2030 | $96.67 | $41.12 | 46.29 |
*Revenue and net income reported in billions
How Eli Lilly’s Next 5 Years Could Play Out
We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years.
For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1250.00. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share.
Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1520.00. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price.
With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1300.00. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued.
By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.00. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation.
Eli Lilly Stocks Price Target for 2030
Price Target: $1850.00
Upside: 132.51%
By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1850.00. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation.
| Year | Price Target | % Change From Current Price |
|---|---|---|
| 2025 | $1140.00 | Upside of 43.28% |
| 2026 | $1250.00 | Upside of 57.10% |
| 2027 | $1520.00 | Upside of 91.03% |
| 2028 | $1300.00 | Upside of 63.38% |
| 2029 | $1623.00 | Upside of 103.98% |
| 2030 | $1850.00 | Upside of 132.51% |
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
